Aspire Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Aspire Capital Advisors's BMY Position: Q2 2026 in Review
Aspire Capital Advisors increased its Bristol-Myers Squibb (BMY) stake by 1.1% in Q2 2026, buying an estimated $6.83K and bringing the position to 11,306 shares worth $651K. The position accounts for 0.13% of the portfolio, ranked #74.
Aspire Capital Advisors first reported a position in BMY in Q3 2025 and has held it in 4 quarters since. The position peaked at $678K in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Aspire Capital Advisors held 11,306 shares of Bristol-Myers Squibb worth $651K as of Q2 2026.
- Aspire Capital Advisors bought 119 Bristol-Myers Squibb shares in Q2 2026, an estimated $6.83K.
- Bristol-Myers Squibb made up 0.13% of Aspire Capital Advisors's portfolio in Q2 2026, its #74 holding.
- Aspire Capital Advisors first reported a position in Bristol-Myers Squibb in Q3 2025 and has held it in 4 quarters since.
- Aspire Capital Advisors's Bristol-Myers Squibb position peaked at $678K in Q1 2026.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Aspire Capital Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.